January 30, 2018
MEMBER/CENTER HIGHLIGHTS
Huang Receives $450,000 from Pediatric Cancer Research Foundation
Alex Huang Alex Huang MD, PhD has received a $450,000 Basic Science grant from the Pediatric Cancer Research Foundation  to study targeted approaches for effectively eliminating metastatic osteosarcoma.

"We're very excited to study an important cancer that occurs in adolescents, young adults and children," said Huang, who is a professor of pediatrics at Case Western Reserve University School of Medicine and co-Leader of the Hematopoietic and Immune Cancer Biology Program of the Case Comprehensive Cancer Center. "We are now on the cusp of clinical trials, and look forward to offering hope to young patients with metastatic osteosarcoma in the near future." more>
Parameswaran Receives Funding for Pediatric Cancer Research
Reshmi Parameswaran Reshmi Parameswaran, PhD is the recipient of a grant from the Andrew McDonough B+ Foundation for her project, Reversing NK cell dysfunction in pediatric cancer. Dr. Parameswaran is an Assistant Professor of Pathology at CWRU and member of the Hematopoietic and Immune Cancer Biology Program of the Case CCC. 
Schiemann Professorship Appointment
William Schiemann Congratulations to William Schiemann, PhD on his appointment as the the Isador Jacob Goodman - Ruth Goodman Blum Professor of Cancer Research. The CWRU School of Medicine is hosting a program and reception this Thursday,  Feb 1 at 4:30p in the Wolstein Research Building. 
Cleveland Clinic Researchers Find New Gene Variant Linked to Deadly Prostate Cancer

Nima Sharifi The research, led by  Nima Sharifi, MD, co-Leader of the GU Malignancies Program at the Case Comprehensive Cancer Center Center and staff in the Cleveland Clinic  Lerner Research Institute  Department of Cancer Biology, shows that men who lack a certain subtype of the gene may be more susceptible to aggressive prostate cancer that does not respond to treatment.

Dr. Sharifi and colleagues built upon their  earlier seminal work in which they discovered that a gene called HSD3B1, when altered, enables prostate tumors to evade treatment and proliferate. They went on to show that the presence of this gene variant does in fact change treatment outcomes and overall survival in men.
In the current study published in Journal  Cell Reports [Ko, Cell Rep, 2018], Dr. Sharifi and his team studied a related gene, called HSD17B4. Previous research showed that HSD17B4 encodes enzymes that inactivate androgens (male hormones). Since androgens are essential for prostate cancer growth, inactivating them should prevent cancer advancement. But these enzymes have also been observed to be more abundant in advanced prostate cancer. Therefore, until now it remained unclear whether the enzymes promote or suppress prostate cancer. more>
Case CCC Researchers Develop Highly Sensitive Swallowable Test to Detect Pre-cancerous Barrett's Esophagus
Investigators at the Case Comprehensive Cancer Center (Case CCC), Case Western Reserve University (CWRU) School of Medicine (SOM) and University Hospitals Cleveland Medical Center (UHCMC) have developed a simple, swallowable test for early detection of Barrett's esophagus (BE) that offers promise for preventing deaths from esophageal adenocarcinoma.

Barrett's esophagus is the precursor lesion of esophageal adenocarcinoma (EAC), a highly lethal cancer with more than 80 percent mortality at five years. Lethal EAC can be prevented when patients are diagnosed at the precursor stage of BE, and early foci of near cancerous changes (dysplasias) are ablated. However, detection of BE has traditionally necessitated endoscopy, an expensive and invasive test that requires sedation and is thus unsuitable as a method for wide BE screening. In a significant step forward, the team has developed an easy, five minute outpatient test that is more than 90 percent sensitive for detecting individuals with BE. Patients simply swallow a vitamin pill sized balloon that swabs the esophagus, and that, after retrieval through the mouth, is tested for DNA abnormalities that the investigators discovered are diagnostic of BE. A study describing the development of the test and the results from its clinical trial in patients has been published in the January 17 issue of  Science Translational Medicine [Moinova, Sci Transl Med, 2018].

The swallowable balloon device was developed by Case CCC members  Amitabh Chak, MD (Professor of Medicine and head of the Barrett's Esophagus Translational Research Network, BETRNet), Joseph Willis, MD (Professor and Pathology Vice-Chair for Clinical Affairs), and Sanford Markowitz, MD, PhD (Co-Leader of the GI Cancer Genetics Program at the Case CCC, Ingalls Professor of Cancer Genetics and head of the Case GI SPORE). Helen Moinova, PhD, study first author and instructor at CWRU SOM, led a parallel effort within the Markowitz laboratory to identify DNA changes diagnostic of Barrett's. Using genome-wide sequencing approaches, Dr. Moinova identified two genes, VIM and CCNA1, that each get chemically modified by DNA methylation in BE. Dr. Moinova's DNA methylation test was more than 90 percent accurate in detecting BE or in recognizing an esophagus as normal in a set of more than 300 esophagus endoscopy samples collected by Dr. Chak's multicenter BETRNet team. Under sponsorship from the SPORE and BETRNet programs, Dr. Chak then led a clinical trial in which 86 individuals were tested using the swallowable esophageal balloon device. Dr. Moinova's DNA assay of these balloon samples was again more than 90 percent accurate, with 90.3 percent sensitivity for detecting individuals with BE and 91.7 percent specificity for correctly identifying individuals who were normal. more>
MARK YOUR CALENDARS
Cancer Center Seminar Series
February 2, 2018 | Wolstein 1-413
CCSS - Feb 2, 2018 Join us Friday, February 2 at noon in Wolstein Research Building Room 1-413 for the weekly Cancer Center Seminar Series to hear Jason S. Lewis, PhD, the Emily Tow Jackson Chair in Oncology, Vice Chair for Research for the Department of Radiology and Chief of the  Radiochemistry and Imaging Sciences Service at Memorial Sloan Kettering Cancer Center, discuss " Molecular Imaging in Cancer: PET Imaging Biomarkers." 

Jason S. Lewis, PhD is the Emily Tow Jackson Chair in Oncology at Memorial Sloan Kettering Cancer Center (MSKCC) and currently serves as Vice Chair for Research and as the Chief of the Radiochemistry & Imaging Sciences Service in MSKCC's Department of Radiology. He is the Director of MSKCC's Radiochemistry and Molecular Imaging Probe Core Facility and is Director of the MSKCC Center for Molecular Imaging & Nanotechnology. His research interests are focused on the development of new molecular imaging agents and radiopharmaceuticals for the diagnosis and treatment of cancer. He has worked on the development of small molecules targeting cancer, as well as radiolabeled peptides and Zr-89-labeled antibodies targeting disease-specific receptors and antigens; this is always with the ultimate goal of clinical translation.
Case CCC Clinical Research Retreat
Feb 27, 2018 | Wolstein Research Building
Registration is open for the next Case Comprehensive Cancer Center Clinical Research Retreat, Tuesday, Feb 27 from 5-7p in the Wolstein Research Building.

Retreat themes:

"Implicit bias, cultural humility, and appropriate communication with racial/ethnic minority cancer patients"
Presented by  Monica Webb Hooper, PhD Director, Office of Cancer Disparities Research Case CCC

"Accrual of patients of minority race and ethnicity: The provider's role"
Presented by Smitha Krishnamurthi, MD, Associate Professor, Hematology and Medical Oncology, CWRU/Cleveland Clinic; Member, Case CCC

1.5 CME Category 2 hours and 4 CRECs will be offered to attendees. Pre-registration is required. Parking passes will be provided. 

Contact Katarzyna Karelus (katarzyna.karelus@case.edu) with questions. 
2nd Annual Cancer Disparities Symposium
Mar 23, 2018 | Wolstein Research Building
The Case Comprehensive Cancer Center and Office of Cancer Disparities Research will host the " 2nd Annual Cancer Disparities Symposium: Taking it to the Streets: Where Cancer Disparities Research and Community Intersect," on  Friday, March 23, 2018
 
This event will showcase cutting-edge research, with a focus on reducing and eliminating disparities in cancer, going from bench-to-bedside-to-community and back. This important symposium will also feature two keynote addresses, including a key leader in our community, and an internationally-recognized cancer disparities researcher. We will promote the exchange of ideas and collaborative opportunities among scientists, clinicians, government, and community representatives.

This event is FREE to attend, but pre-registration is required. 
Midwest DNA Repair Symposium
May 5-6, 2018 | Thwing Center
The Case Comprehensive Cancer Center and Case Western Reserve University will host the 20th Annual Midwest DNA Repair Symposium May 5-6, 2018 . This symposium is a great opportunity for people working on DNA damage and repair in the midwest area to gather together and discuss science! The agenda promises exciting science and opportunities for networking, poster presentations, and keynote presentations from field experts  Stephen Kowalczykowski and Lee Zou

Call for Abstracts
The 20th Annual Midwest DNA Repair Symposium will feature oral and poster presentations.  All graduate students, postdocs, research technician, faculty and fellows conducting related research are invited to submit abstracts. Monetary Prizes will be awarded.

Abstracts must be 500 words or less and fit on an 8 ½ x 11" paper with 1" margins on all sides. Please use Arial 11 font. 

Include the title and authors at the top, acknowledgements at the bottom. You may include figures or illustrations, but they must fit on the same page as the abstract text.  Please indicate whether you prefer oral or poster presentation.

Abstract submission deadline is Monday, April 2 at 5pm to maw143@case.edu
Cancer Stem Cells 2018
Aug 6-8, 2018 | Tinkham Veale University Center
The Cancer Stem Cell Conference (CSC 2018), hosted by the Case Comprehensive Cancer Center and National Center for Regenerative Medicine, is designed to bring together individuals working in the field of cancer stem cell research. CSC 2018 will feature renowned keynote speakers and leaders in the field. This conference is guaranteed to have cutting edge research from a variety of niches within the field.

Registration will open soon - watch this newsletter for updates! 
FUNDING OPPORTUNITIES
BETRNet Pilot Project Award Program
Deadline: Jan 31, 2018
The CWRU Barrett's Esophagus Translational Research Network (BETRNet) Research Center, supported by NIH/NCI U54CA163060, announces a program to encourage innovative transdisciplinary and translational research related to Barrett's Esophagus (BE). The overall objectives of the program are: 1) to encourage innovative transdisciplinary and translational research, especially high risk/high impact research; 2) to explore emerging opportunities and to enhance productivity of the research projects in the BETRNet, and; 3) to attract new researchers, resources and technologies to conduct translational research on BE and Esophageal Adenocarcinoma (EAC).  

Limited awards of up to $40,000/year will be made to eligible applicants for one year, with the possibility of a second year of funding based on the success of the pilot. Pilot projects must have a transdisciplinary approach and translational research plan focused on BE and/or EAC in one of the focus areas defined by BETRNet.
American Cancer Society Research Professor Grants
Letter of Intent Deadline: February 1, 2018
Application Deadline: April 2, 2018
The American Cancer Society offers a limited number of grants to mid-career investigators who have made seminal contributions that have changed the direction of basic cancer research. Furthermore, it is expected that these investigators will continue to provide leadership in their research area. Up to two awards are made annually for a five-year term that can be renewed once. The award of up to $80,000 per year (direct costs only) may be used for salary or research project support.
Jane Coffin Childs Memorial Fund for Medical Research
Deadline: Feb 1, 2018
The Jane Coffin Childs Memorial Fund for Medical Research is accepting applications for fellowships. Fellowship appointments are for three years. 

Eligibility: 
  • Postdoctoral applicants should have no more than one year of postdoctoral research experience at the time of the deadline for submitting applications
  • PhD. degree must not have been conferred more than 18 months prior to the deadline date 
  • MD. degree should not have been conferred more than three years before deadline date of application
  • PhD. candidates that do not have their degree at time of application deadline are eligible to apply. If awarded, the applicant's PhD degree must be conferred prior to the start of the Fellowship.
LIMITED SUBMISSION: Damon Runyon Cancer Research Foundation
Deadline: Feb 1, 2018 at 4p
The Damon Runyon Cancer Research Foundation is accepting applications for the Clinical Investigator Award. 
This award supports independent young physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. The goal is to support the best young physician-scientists doing work aimed at improving the practice of cancer medicine. 

The Clinical Investigator Award responds to three recognized realities:
  • Though there has never been a more pressing need or more promising time for clinical cancer research, fewer young physicians enter this area of investigation every year.
  • The number of institutions committed to training young physicians in the scientific discipline and methodologies of clinical investigation is critically low.
  • The burden of medical school debt (averaging over $100,000) discourages many physicians from pursuing clinical investigation.
Interested applicants should submit documents to Cynthia Rahn (cynthia.rahn@case.edu; 216.368.2285), CWRU SOM Foundation Relations. 
Bladder Cancer Advocacy Network (BCAN) 

LOI Deadline: Feb 21, 2018
In 2014, BCAN announced the  Bladder Cancer Research Innovation Award of $300,000 over a two-year period for an experienced investigator who will break new ground in the field of  bladder cancer.  The aim of the award is to support exceptionally novel and creative projects with great potential to produce breakthroughs in the management of  bladder cancer.

Deadline: Feb 26, 2018
Raising the bar on research, BCAN launched its Young Investigator Awards in 2013. These one year $50,000 grants fund researchers who may be working in basic, translational, clinical, epidemiologic, bioengineering or any other scientific or research field, but are also working in a research environment capable of supporting transformational  bladder cancer research. The program was seeded through a $250,000 challenge grant received from the Gerald C. McNamara and Renée K. Petrofes Charitable Fund. Case CCC member Bryon Lee, MD, PhD received this award in 2017. 

Deadline: Feb 26, 2018
For the first time, BCAN is designating an additional YIA for  Patient-Centered Clinical Research.  To compete for this award, investigators must be working in a research environment capable of supporting transformational patient-oriented clinical bladder cancer research (e.g. studies of access to care, quality of care, quality of life, health disparities, and patient-centered outcomes research).
Burroughs Wellcome Fund Career Guidance for Trainees (CGT) Program
Deadline: Mar 6, 2018
The Career Guidance for Trainees (CGT) program provides grants of $30,000-$50,000 over a one-year period to support demonstration projects that will model affordable approaches to improving trainees' readiness for stable, fulfilling careers, whether by clarifying and improving their basic "PhD-level" skills, by helping them identify how they can best use their skills and interests to serve the needs of potential employers, by providing them approaches to thinking through their career options, or by other strategies.

This fifth call for proposals is open to both single institutions and institutions working in partnerships. Academic institutions, professional societies, and advocacy organizations are among the appropriate drivers of proposals. Only non-profit institutions may be supported by BWF's award, but non-profits may involve for profit organizations in their proposals. Proposals in which professional societies serving different fields or sectors collaborate with one another are encouraged, as are proposals between different Units or Schools within an academic institution.

Conference calls will be held on Feb 2, 2018 and Feb 15, 2018 to provide general information. 
IN THE NEWS
Digging for Gold
Radiology Today - Vol 18, No 12, Pt 16
The difference between radiomics and CAD, deep learning, or AI is the human factor, says Anant Madabhushi, PhD, Case Comprehensive Cancer Center, professor in the department of biomedical engineering and director of the Center for Computational Imaging and Personalized Diagnostics at Case Western Reserve University in Cleveland. The radiologist using radiomics is able to apply his intuition to what he sees and what the data sets tell him or her, he says.  "There are folks who are critical of deep learning because of its lack of intuitiveness," Madabhushi says. "Deep learning or AI is based on what the machine thinks. Radiomics combines the best the human reader and the machine can do, which takes it to the next level."...Researchers at Case Western are also studying features captured from MR enterography to develop a treatment score that could be used to predict patient response to therapy for Crohn's disease. "Satish Viswanath, PhD, an assistant professor of biomedical engineering at Case Western, and his team are looking to develop a radiographic enterographic treatment score that can help us distinguish between mild and severe Crohn's," Madabhushi says.
US News and World Report - Jan 15, 2018
...As it continues to grow, it will deform the entire testicle, causing it to become larger than the normal one. As Petinga learned, a shrinking testicle can also be a sign of testicular cancer. "It's not common, but it can happen," says Dr. Timothy Gilligan, Case Comprehensive Cancer Center, medical oncologist at the Cleveland Clinic.  
Bloomberg Businessweek - Jan 11, 2018
People who've shirked their exams often number among the 50,000 Americans who die from colon cancer each year. "More non-invasive ways of screening are needed," says Matthew Kalady, Case Comprehensive Cancer Center, co-director of the colorectal cancer program at the Cleveland Clinic. "If you could pick up colon cancer early and noninvasively with a sample blood test, that would be just fantastic."
NIH BULLETIN- Notices and Funding Opportunities
rfas 
Program Announcements

Programs to Increase Diversity Among Individuals Engaged in Health-Related Research (PRIDE) (R25 Clinical Trial Not Allowed)(RFA-HL-19-002)


PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)(PA-18-573)  

PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)(PA-18-574)

PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)(PA-18-575)

PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)(PA-18-576)  

Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01, Clinical Trials Not Allowed)(PAR-18-583)

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)(PA-18-586)

Successor-in-Interest (Type 6 Parent Clinical Trial Optional)(PA-18-589)

Change of Grantee Organization (Type 7 Parent Clinical Trial Optional)(PA-18-590)

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp - Clinical Trial Optional)(PA-18-591)

Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp - Clinical Trial Not Allowed)(PA-18-592)

Notices

Notice of Correction to PA-18-517, "Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp - Clinical Trial Not Allowed)"

NCI Method to Extend Research in Time (MERIT) Award for Early Stage Investigators (R37)(NOT-CA-18-037)

Notice of Expiration of PAR-15-308, "Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (R01)" (NOT-CA-18-038)
 
Notice of Expiration of PAR-15-309, "Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (R21)" (NOT-CA-18-039)
 
Notice of Expiration of PAR-16-249, "Innovative Approaches to Studying Cancer Communication in the New Media Environment (R01)"(NOT-CA-18-040)

Notice of Expiration of PAR-17-124 "Perception and Cognition Research to Inform Cancer Image Interpretation (R21)" (NOT-CA-18-042)
 
Notice of Expiration of PAR-17-125 "Perception and Cognition Research to Inform Cancer Image Interpretation (R01)" (NOT-CA-18-043) 

Notice of Expiration of PAR-16-212 "Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01)"(NOT-CA-18-044)
 
Notice of Expiration of PAR-16-213 "Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21)"(NOT-CA-18-045)
 
Notice of Expiration of PAR-17-217 "U.S. Tobacco Control Policies to Reduce Health Disparities (R01)"(NOT-CA-18-046)
 
Notice of Expiration of PAR-17-218 "U.S. Tobacco Control Policies to Reduce Health Disparities (R21)"(NOT-CA-18-047)
 
Notice of Expiration for RFA-CA-17-019, "Revision Applications to NCI-supported R01 Awards to Include Research on the NCI's Provocative Questions (R01)"(NOT-CA-18-048)
 
Notice of Expiration for RFA-CA-17-020, "Revision Applications to National Cancer Institute (NCI)-supported U01 Awards to Include Research on the NCI's Provocative Questions (U01)" (NOT-CA-18-049)
 
Notice of Expiration for RFA-CA-17-021, "Revision Applications to National Cancer Institute (NCI)-supported P01 Awards to Include Research on the NCI's Provocative Questions (P01)(NOT-CA-18-050)
 
Notice of Expiration for RFA-CA-17-022, "Revision Applications to National Cancer Institute (NCI)-supported P50 Awards to Include Research on the NCI's Provocative Questions (P50)(NOT-CA-18-051) 
EVENTSevents
Thurs, Feb 1
Developmental Therapeutics Journal Club
9a R4-013

Program and Reception celebrating the appointment of William P. Schiemann, PhD as the Isador Jacob Goodman - Ruth Goodman Blum Professor of Cancer Research
4:30p WRB 1-413
Fri, Feb 2
Hem Onc Grand Rounds Special Presentation
Daniel Lee, MD, PhD Oncology Fellow, National Cancer Institute, National Institutes of Health
"miR-769-5p is a Prostate oncomiR"
8a Wearn 137

Taussig Cancer Institute Grand Rounds
David Carbone, MD Ohio State University "Lung Cancer - Finding Science-based Progress for a Major Health Problem"
8a CA5-120

Cellular and Molecular Medicine
Li Li, MD, PhD
Associate Director for Prevention Research, Case CCC
Professor, Family Medicine, CWRU
"Gut Microbiome, Lifestyle Risk Factors and Colon Adenoma"
10a NC1-202

Cancer Center Seminar Series
Jason Lewis, PhD
Emily Tow Jackson Chair in Oncology
Vice Chair for Research, Department of Radiology
Chief Radiochemistry and Imaging Sciences Service
Memorial Sloan Kettering Cancer Center
"Molecular Imaging in Cancer: PET Imaging Biomarkers"
12p WRB 1-413
Mon, Feb 5
Genomic Medicine Institute
Stetson Thacker
Eng Lab, Genomic Medicine Institute, Cleveland Clinic "Constitutional Pten Mutation Alters Alternative Splicing Patterns in the Brain, Contributing to an Autism Phenotype"
12p NE1-205

Cancer Center Research Chalk Talk
Zhenghe John Wang, PhD
Professor, Genetics and Genomic Sciences, CWRU
Co-Leader, GI Cancer Genetics Program, Case CCC
1p WRB 3-136

Tumor Immunology and Immunotherapy
Mari Dallas, MD
Associate Professor, Hematology and Oncology, CWRU/UH
4p WRB 3-136
Tues, Feb 6
THOR Seminar
Ulrich Steidl, MD, PhD
Professor, Medical Oncology, Albert Einstein College of Medicine
1p NE1-205

Cancer Center Research in Progress
3p WRB 3-136
Wed, Feb 7
Best of San Antonio Breast Cancer Symposium
7:45a-4:30p Embassy Suites Hotel,  Independence
Details

Immunology Students/Fellows Research In Progress Series
Julien Audry, PhD
Postdoctoral Fellow, Runge Lab
Junjie Zhao, PhD, Postdoctoral Fellow, Li Lab
12p NC1-202

Virology Journal Club

Angelica Cruz Lebron
12p Wood RT 206
Thurs, Feb 8
Developmental Therapeutics Journal Club
9a R4-013

Molecular Biology and Microbiology Seminar
Curtis Dobrowolski
Karn lab, CWRU
"Using EDITS to Understand the Epigenetic Differences between Memory T Cell Subsets in Well Suppressed HIV Patients"
1p SOM W203

2017 Science Nobel Prizes - What were they given for? 
Harsh Mathur: Physics Prize
Phoebe Stewart: Chemistry Prize
Peter Harte: Medicine or Physiology Prize

4p Rockefeller 301
Fri, Feb 9
Taussig Cancer Institute Grand Rounds
Sameek Roychowdhury, MD
Ohio State University "Patients Teaching Us How to Develop Novel Markers, Diagnostics, and Therapies to Beat Cancer"
8a CA5-120

Cancer Center Seminar Series
Anthony F. Shields, MD, PhD
Professor, Oncology and Medicine, Wayne State University
Associate Director for Clinical Sciences, Karmanos Cancer Institute
12p WRB 1-413

ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
prev-funding
PREVIOUSLY ANNOUNCED OPPORTUNITIES

Case Comprehensive Cancer Center 
11100 Euclid Avenue, Wearn152
Cleveland, OH 44106-5065